Literature DB >> 17996311

Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system.

Matthew P Stevens1, Suzanne M Garland, Sepehr N Tabrizi.   

Abstract

The recently released Linear Array human papillomavirus (HPV) genotyping test (Roche Diagnostics) provides a standardized method for simultaneous detection of up to 37 individual HPV types. This test offers a rapid approach for detecting and longitudinal monitoring of patients infected with high-risk (HR) HPV. However, it cannot rule out HPV52 infections in the presence of carcinogenic HPV genotypes 33, 35 and/or 58. As such, often only a non-definitive result of HPV52 presence can be reported. This study describes the development of a real-time PCR assay using an HPV52-specific hydrolysis probe in conjunction with the newly released Roche LightCycler 480 system. HPV52 was readily detected among DNA extracts from samples previously identified with possible HPV52 by the linear array test. Specificity was analyzed using a panel of DNA extracts previously identified as containing single/multiple HPV types, with or without HPV52. This is a rapid and simple assay, which could be used as a supplementary test to the Linear Array, to verify the presence or absence of HPV52 among samples testing positive for either HPV33, 35, and/or 58. Laboratories already using the Linear Array HPV genotyping test could adopt this method once internally validated.

Entities:  

Mesh:

Year:  2007        PMID: 17996311     DOI: 10.1016/j.jviromet.2007.09.018

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  14 in total

1.  Comparison of PapType to Digene Hybrid Capture 2, Roche linear array, and Amplicor for detection of high-risk human papillomavirus genotypes in women with previous abnormal pap smears.

Authors:  Sepehr N Tabrizi; Matthew P Stevens; Zaheer A Khan; Conan Chow; Martin A Devitt; Suzanne M Garland
Journal:  J Clin Microbiol       Date:  2012-05-30       Impact factor: 5.948

2.  The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.

Authors:  Carina Eklund; Ola Forslund; Keng-Ling Wallin; Tiequn Zhou; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

3.  Global proficiency study of human papillomavirus genotyping.

Authors:  Carina Eklund; Tiequn Zhou; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2010-09-15       Impact factor: 5.948

4.  Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study.

Authors:  Carina Eklund; Ola Forslund; Keng-Ling Wallin; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2013-11-20       Impact factor: 5.948

5.  Comparison of two PCR-based human papillomavirus genotyping methods.

Authors:  Philip E Castle; Carolina Porras; Wim G Quint; Ana Cecilia Rodriguez; Mark Schiffman; Patti E Gravitt; Paula González; Hormuzd A Katki; Sandra Silva; Enrique Freer; Leen-Jan Van Doorn; Silvia Jiménez; Rolando Herrero; Allan Hildesheim
Journal:  J Clin Microbiol       Date:  2008-08-20       Impact factor: 5.948

6.  The epidemiology of human papillomavirus infection in HIV-positive and HIV-negative high-risk women in Kigali, Rwanda.

Authors:  Nienke J Veldhuijzen; Sarah L Braunstein; Joseph Vyankandondera; Chantal Ingabire; Justin Ntirushwa; Evelyne Kestelyn; Coosje Tuijn; Ferdinand W Wit; Aline Umutoni; Mireille Uwineza; Tania Crucitti; Janneke H H M van de Wijgert
Journal:  BMC Infect Dis       Date:  2011-12-02       Impact factor: 3.090

7.  Laser capture microdissection as a tool to evaluate human papillomavirus genotyping and methylation as biomarkers of persistence and progression of anal lesions.

Authors:  Alyssa M Cornall; Jennifer M Roberts; Monica Molano; Dorothy A Machalek; Samuel Phillips; Richard J Hillman; Andrew E Grulich; Fengyi Jin; I Mary Poynten; David J Templeton; Suzanne M Garland; Sepehr N Tabrizi
Journal:  BMJ Open       Date:  2015-08-26       Impact factor: 2.692

8.  Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand.

Authors:  Leonardo M Simonella; Hazel Lewis; Megan Smith; Harold Neal; Collette Bromhead; Karen Canfell
Journal:  BMC Infect Dis       Date:  2013-03-03       Impact factor: 3.090

9.  Investigating a cluster of vulvar cancer in young women: a cross-sectional study of genital human papillomavirus prevalence.

Authors:  Alice R Rumbold; Sarah E Tan; John R Condon; Debbie Taylor-Thomson; Maria Nickels; Sepehr N Tabrizi; Margaret L J Davy; Margaret M O'Brien; Christine M Connors; Ibrahim Zardawi; Jim Stankovich; Suzanne M Garland
Journal:  BMC Infect Dis       Date:  2012-10-05       Impact factor: 3.090

10.  Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study).

Authors:  Elisa J Young; Sepehr N Tabrizi; Julia Ml Brotherton; John D Wark; Jan Pyman; Marion Saville; C David Wrede; Yasmin Jayasinghe; Jeffrey Tan; Dorota M Gertig; Marian Pitts; Suzanne M Garland
Journal:  BMC Cancer       Date:  2013-06-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.